Eli Lilly: The Buzz Is Not Over

jetcityimage Investment Thesis I believe Eli Lilly (NYSE:LLY) is poised for continual growth due to the significant demand for weight-loss drugs and the increasing insurance coverage. My perspective is a belief in the future of GLP-1 therapies, particularly those targeting obesity. My main focus is on Eli Lilly's pioneering drug, Zepbound, which I see tackling weight-related health issues- we could almost think of this new division of obesity management as a growth segment in the company, at least that's ho ...